IRIS
Del Re, Marzia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 1.925
NA - Nord America 1.500
SA - Sud America 775
EU - Europa 262
AF - Africa 107
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 1
Totale 4.573
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.387
SG - Singapore 713
BR - Brasile 590
CN - Cina 362
HK - Hong Kong 283
VN - Vietnam 153
IT - Italia 107
MX - Messico 83
IN - India 81
AR - Argentina 61
BD - Bangladesh 56
IQ - Iraq 54
CO - Colombia 40
TR - Turchia 38
EC - Ecuador 29
ID - Indonesia 29
SA - Arabia Saudita 27
RU - Federazione Russa 26
ZA - Sudafrica 24
VE - Venezuela 23
PK - Pakistan 21
GB - Regno Unito 19
PH - Filippine 19
FR - Francia 17
MA - Marocco 15
NL - Olanda 15
UZ - Uzbekistan 14
UA - Ucraina 13
ES - Italia 12
MY - Malesia 12
DE - Germania 11
TN - Tunisia 11
DZ - Algeria 10
CA - Canada 9
JO - Giordania 9
KE - Kenya 9
PY - Paraguay 9
EG - Egitto 8
BO - Bolivia 7
AZ - Azerbaigian 6
CL - Cile 6
PS - Palestinian Territory 6
RS - Serbia 6
KZ - Kazakistan 5
UY - Uruguay 5
AE - Emirati Arabi Uniti 4
AO - Angola 4
CR - Costa Rica 4
IE - Irlanda 4
LB - Libano 4
NG - Nigeria 4
NP - Nepal 4
PE - Perù 4
ET - Etiopia 3
HN - Honduras 3
HU - Ungheria 3
IR - Iran 3
JM - Giamaica 3
NO - Norvegia 3
OM - Oman 3
PT - Portogallo 3
TH - Thailandia 3
TT - Trinidad e Tobago 3
ZW - Zimbabwe 3
BA - Bosnia-Erzegovina 2
BE - Belgio 2
BG - Bulgaria 2
BH - Bahrain 2
BY - Bielorussia 2
CG - Congo 2
DO - Repubblica Dominicana 2
FI - Finlandia 2
GE - Georgia 2
IL - Israele 2
KR - Corea 2
LT - Lituania 2
MU - Mauritius 2
PL - Polonia 2
RO - Romania 2
SN - Senegal 2
UG - Uganda 2
AM - Armenia 1
AU - Australia 1
BB - Barbados 1
CH - Svizzera 1
CM - Camerun 1
CY - Cipro 1
CZ - Repubblica Ceca 1
GM - Gambi 1
GR - Grecia 1
GT - Guatemala 1
HR - Croazia 1
JP - Giappone 1
KG - Kirghizistan 1
KW - Kuwait 1
LK - Sri Lanka 1
LY - Libia 1
MD - Moldavia 1
MT - Malta 1
MZ - Mozambico 1
Totale 4.558
Salva come PNG Salva come JPEG
Città #
San Jose 915
Singapore 406
Hong Kong 275
Ashburn 251
Beijing 161
Ho Chi Minh City 71
Mexico City 65
Rome 41
São Paulo 29
Santa Clara 26
Hanoi 24
Rio de Janeiro 22
Istanbul 15
Milan 14
Baghdad 13
Lahore 13
Medellín 13
Brasília 12
Caracas 12
Curitiba 12
Tashkent 12
Dhaka 11
Belo Horizonte 10
Jeddah 10
Quito 10
Ribeirão Preto 10
Amman 9
Haiphong 9
Nairobi 9
New York 9
Orem 9
Bogotá 8
Guayaquil 8
Moscow 8
Riyadh 8
Campinas 7
Council Bluffs 7
Goiânia 7
Jakarta 7
São José dos Campos 7
Tunis 7
Asunción 6
Baku 6
Da Nang 6
Erbil 6
Johannesburg 6
Karbala 6
Osasco 6
Salvador 6
Belém 5
Biên Hòa 5
Buenos Aires 5
Canoas 5
Cape Town 5
Fortaleza 5
Hyderabad 5
Kuala Lumpur 5
La Paz 5
Porto Alegre 5
Anápolis 4
Bauru 4
Belgrade 4
Casablanca 4
Dammam 4
Feira de Santana 4
Guarulhos 4
Kirkuk 4
Lima 4
Manaus 4
Medina 4
Montevideo 4
New Delhi 4
Niterói 4
Pelotas 4
Pune 4
Quezon City 4
Rabat 4
Rondonópolis 4
San Antonio 4
Taubaté 4
Vitória da Conquista 4
Addis Ababa 3
Algiers 3
Aracaju 3
Araraquara 3
Atlanta 3
Berazategui 3
Caloocan 3
Can Tho 3
Cartagena 3
Ceres 3
Delhi 3
Dublin 3
Duque de Caxias 3
Faisalabad 3
Harare 3
Houston 3
Itajaí 3
Jaipur 3
Juazeiro do Norte 3
Totale 2.815
Salva come PNG Salva come JPEG
Nome #
AR-V7 and AR-FL expression is associated with clinical outcome: a translational study in patients with castrate resistant prostate cancer 47
Blood-based PD-L1 analysis in tumor-derived extracellular vesicles: Applications for optimal use of anti-PD-1/PD-L1 axis inhibitors 41
CDK4/6 Inhibitors Overcome Endocrine ESR1 Mutation-Related Resistance in Metastatic Breast Cancer Patients 40
EGFR signaling pathway as therapeutic target in human cancers 39
Cost-effectiveness of treatment optimisation with biomarkers for immunotherapy in solid tumours: A systematic review protocol 37
Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs 36
PI3K mutations detected in liquid biopsy are associated to reduced sensitivity to CDK4/6 inhibitors in metastatic breast cancer patients 36
ALK Inhibitors in Patients With ALK Fusion-Positive GI Cancers: An International Data Set and a Molecular Case Series 35
Droplet digital PCR represents a new sensitive method for detecting B-RAFV600E mutation at diagnosis and during the follow-up of patients affected by hairy cell leukemia 35
A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC 35
Quantitative and Qualitative Analysis of Blood-based Liquid Biopsies to Inform Clinical Decision-making in Prostate Cancer 35
Immune Checkpoint Inhibitors and Cardiotoxicity: An Analysis of Spontaneous Reports in Eudravigilance 34
DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients 34
Molecular screening with liquid biopsy for anti-EGFR retreatment in metastatic colorectal cancer: preliminary data from the randomized phase 2 PARERE trial 34
Pharmacokinetic and pharmacogenetic predictive markers of irinotecan activity and toxicity 33
Gene network Analysis Defines a Subgroup of Small Cell Lung Cancer patients With Short Survival 33
Do peripheral neuropathies differ among immune checkpoint inhibitors? Reports from the European post-marketing surveillance database in the past 10 years 32
Empower the potential of trastuzumab deruxtecan with novel combinations 32
Circulating Tumor DNA as a Marker of Minimal Residual Disease After Radical Resection of Colorectal Liver Metastases 32
Gemcitabine plus nab-paclitaxel induces PD-L1 mRNA expression in plasma-derived microvesicles in pancreatic cancer 31
Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclib 31
The tumor-agnostic treatment for patients with solid tumors: a position paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIF Italian Scientific Societies 31
DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis 31
Optimized granulocyte colony-stimulating factor prophylaxis in adult cancer patients: from biological principles to clinical guidelines 31
Pharmacogenetic foundations of therapeutic efficacy and adverse events of statins 30
Concomitant Administration of VEGFR Tyrosine Kinase and Proton Pump Inhibitors May Impair Clinical Outcome of Patients With Metastatic Renal Cancer 30
Updates on liquid biopsy: Current trends and future perspectives for clinical application in solid tumors 30
Liquid Biopsy of Lung Cancer Before Pathological Diagnosis Is Associated With Shorter Time to Treatment 30
Benefits and Harms of Lung Cancer Screening by Chest Computed Tomography: A Systematic Review and Meta-Analysis 30
Understanding mechanisms of resistance to FLT3 inhibitors in adult FLT3-mutated Acute Myeloid Leukemia (AML) to guide treatment strategy 29
Drug-drug interactions in breast cancer patients treated with CDK4/6 inhibitors 29
The Genetic Basis of Dormancy and Awakening in Cutaneous Metastatic Melanoma 29
What do we need to obtain high quality circulating tumor DNA (ctDNA) for routine diagnostic test in oncology? – Considerations on pre-analytical aspects by the IFCC workgroup cfDNA 29
Facing an un-met need in lung cancer screening: The never smokers 29
Pharmacology differences among proteasome inhibitors: Implications for their use in clinical practice 29
Segmentectomy vs. Lobectomy in stage IA non-small cell lung cancer: A systematic review and meta-analysis of perioperative and survival outcomes 29
Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials 29
Recurrent USP6 rearrangement in a subset of atypical myofibroblastic tumours of the soft tissues: low-grade myofibroblastic sarcoma or atypical/malignant nodular fasciitis? 28
Comparison of variant allele frequency and number of mutant molecules as units of measurement for circulating tumor DNA 28
Erratum: Clinical pharmacology of monoclonal antibodies targeting PD-1 axis in urothelial cancers 28
ANKRd44 gene silencing: A putative role in trastuzumab resistance in HER2-like breast cancer 28
Combining liquid biopsy and radiomics for personalized treatment of lung cancer patients. State of the art and new perspectives 28
Nanopore sequencing from liquid biopsy: analysis of copy number variations from cell-free DNA of lung cancer patients 28
Cross-Linked Hyaluronic Acid as Tear Film Substitute 28
Author's reply. Should CYP2D6 be genotyped when treating with tamoxifen? Pharmacogenomics 28
Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: implications for personalised treatment 27
Liquid biopsies from pleural effusions and plasma from patients with malignant pleural mesothelioma: A feasibility study 27
Treatment of advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines 27
KRAS inhibition in non–small cell lung cancer: Past failures, new findings and upcoming challenges 27
nmCRPC, a look in the continuous care of prostate cancer patients: state of art and future perspectives 27
β3-adREnoceptor Analysis in CORD Blood of Neonates (β3 RECORD): Study Protocol of a Pilot Clinical Investigation 27
Multidisciplinary management of HER2-positive breast cancer with brain metastases: An evidence-based pragmatic approach moving from pathophysiology to clinical data 27
The emerging role of liquid biopsy in diagnosis, prognosis and treatment monitoring of pancreatic cancer 27
Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide 27
Identification of a targetable KRAS-mutant epithelial population in non-small cell lung cancer 27
Concise Review: Chronic Myeloid Leukemia: Stem Cell Niche and Response to Pharmacologic Treatment 27
A real-world application of liquid biopsy in metastatic colorectal cancer: The poseidon study 27
The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide 27
Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies 27
Matching BRCA and prostate cancer in a public health system: Report of the Italian Society for Uro-Oncology (SIUrO) consensus project 27
Clinical utility of Next Generation Sequencing of plasma cell-free DNA for the molecular profiling of patients with NSCLC at diagnosis and disease progression 27
Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours 27
EGFR-TKIs in non-small-cell lung cancer: Focus on clinical pharmacology and mechanisms of resistance 26
Endothelial nitric oxide synthase c.-813C>T predicts for proteinuria in metastatic breast cancer patients treated with bevacizumab-based chemotherapy 26
Author's reply 26
Diagnosis and treatment of early and locally advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines 26
Expression of Circulating let-7e and miR-126 May Predict Clinical Remission in Patients With Crohn's Disease Treated With Anti-TNF-α Biologics 26
Genome Wide Association Studies (GWAS) 26
Targeting HER2 in breast cancer with brain metastases: A pharmacological point of view with special focus on the permeability of blood-brain barrier to targeted treatments 26
Liquid Biopsy Response Evaluation Criteria in Solid Tumors (LB-RECIST) 26
Pharmacodynamics, clinical findings and approval status of current and emerging tyrosine-kinase inhibitors for pancreatic neuroendocrine tumors 26
Understanding EGFR heterogeneity in lung cancer 26
Should CYP2D6 be genotyped when treating with tamoxifen? 26
Oral selective estrogen receptor degraders for breast cancer treatment: focus on pharmacological differences 26
Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial 26
Exploring the epigenetic susceptibility mechanisms of lung cancer through DNA methylation markers 26
Clinical CYP2D6 Genotyping to Personalize Adjuvant Tamoxifen Treatment in ER-Positive Breast Cancer Patients: Current Status of a Controversy 25
Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer 25
Digital Droplet PCR in Hematologic Malignancies: A New Useful Molecular Tool 25
The molecular profiling of solid tumors by liquid biopsy: a position paper of the AIOM–SIAPEC-IAP–SIBioC–SIC–SIF Italian Scientific Societies 25
Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm 25
Recommendations for using molecular assays on liquid biopsy: the first document provided by intersociety Group AIOM, SIF, SIAPEC-IAP, SIBioC | Raccomandazioni per l’esecuzione di indagini molecolari su biopsia liquida in oncologia 25
The role of molecular heterogeneity targeting resistance mechanisms to lung cancer therapies 25
Druggable targets meet oncogenic drivers: opportunities and limitations of target-based classification of tumors and the role of Molecular Tumor Boards 25
Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients 25
Application of a pharmacokinetic/pharmacogenetic approach to assess the nicotine metabolic profile of smokers in the real-life setting 25
The increase in activating EGFR mutation in plasma is an early biomarker to monitor response to osimertinib: a case report 25
Genetic variation: effect on prostate cancer 25
Glycemic control and cancer outcomes in oncologic patients with diabetes: an Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), Italian Society of Endocrinology (SIE), Italian Society of Pharmacology (SIF) multidisciplinary critical view 24
Covalent Bruton tyrosine kinase inhibitors across generations: A focus on zanubrutinib 24
The expanding family of c-Met inhibitors in solid tumors: a comparative analysis of their pharmacologic and clinical differences 24
The amount of DNA combined with TP53 mutations in liquid biopsy is associated with clinical outcome of renal cancer patients treated with immunotherapy and VEGFR-TKIs 24
Molecular analysis of cell-free circulating DNA for the diagnosis of somatic mutations associated with resistance to tyrosine kinase inhibitors in non-small-cell lung cancer 24
Mathematical modeling of drug resistance due to KRAS mutation in colorectal cancer 24
DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer 24
IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patients 24
Angiogenic inhibitors in gastric cancers and gastroesophageal junction carcinomas: A critical insight 24
Author's reply. The detection of AR-V7 in plasma-derived exosomal RNA strongly predicts resistance to hormonal therapy in metastatic prostate cancer patients 24
Reply to Ugo De Giorgi, Vincenza Conteduca, and Emanuela Scarpi's Letter to the Editor re: Marzia Del Re, Elisa Biasco, Stefania Crucitta, et al. The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. Eur Urol 2017;71:680–7 24
Integrating Liquid Biopsy and Radiomics to Monitor Clonal Heterogeneity of EGFR-Positive Non-Small Cell Lung Cancer 23
Totale 2.851
Salva come PNG Salva come JPEG
Categoria #
all - tutte 18.769
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 18.769
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2024/20251.169 0 0 0 44 19 50 69 149 168 33 309 328
2025/20263.611 176 38 271 244 467 265 441 256 1.089 364 0 0
Totale 4.780